Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.

This study is testing a combination of three drugs — chidamide (a targeted drug), decitabine (a type of chemotherapy), and an anti-PD-1 antibody (an immunotherapy) — in people with relapsed or treatment-resistant classical Hodgkin lymphoma who cannot have or have refused a stem cell transplant. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with classical Hodgkin lymphoma confirmed by biopsy - You have had at least 2 prior lines of treatment - You are not eligible for a stem cell transplant or have refused one - You have at least one measurable lymph node greater than 1 cm - Your liver, kidney, bone marrow, and heart function are adequate **You may NOT be eligible if...** - You have already received the specific combination of chidamide + decitabine + anti-PD-1 antibody, or brentuximab + anti-PD-1 antibody - You have an autoimmune disease requiring steroid treatment - You have active serious infections, especially lung infections - You have a history of serious gastrointestinal bleeding Talk to your doctor to see if this trial is right for you.